Upgrade to SI Premium - Free Trial

Leerink Partners Reiterates Outperform Rating on Cytokinetics (CYTK) following conference

March 10, 2026 10:28 AM
Leerink Partners analyst Roanna Ruiz reiterated an Outperform rating and $84.00 price target on Cytokinetics (NASDAQ: CYTK)The analyst commented, "Bottom ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments